{"filings":[{"id":94642,"accession_number":"0001104659-26-044890","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Mustang Bio receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 15, 2026 for non-compliance with minimum bid price rule after 30 consecutive business days below $1.00.","Has 180-calendar day grace period until October 12, 2026 to regain compliance by closing at $1.00+ for 10 consecutive business days.","May qualify for second 180-day period if meets Nasdaq continued listing criteria and provides written notice of intent to cure.","Could face delisting if unable to regain compliance; no decision yet on specific actions to remedy deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123499,"accession_number":"0001104659-25-124189","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Mustang Bio terminates CD20 CAR-T license with Fred Hutch, pays $730K to settle $1.4M in payables","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated CD20 CAR-T license with Fred Hutch; agreed to pay $730,000 to settle ~$1.4M in outstanding payables.","Fred Hutch to pay Mustang at least 10% of consideration from any third-party CD20 licensing within three years.","All four proposals passed at Dec 22 annual meeting: directors elected, KPMG ratified, ESPP shares raised to 259,333, EIP to 2,514,666."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140175,"accession_number":"0001104659-25-066520","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mustang Bio gets FDA Orphan Drug Designation for MB-101 CAR T-cell therapy in astrocytomas and glioblastoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Orphan Drug Designation to MB-101 for recurrent diffuse/anaplastic astrocytoma and glioblastoma.","Designation provides tax credits, fee waivers, and potential 7-year market exclusivity upon approval.","Phase 1 trial showed 50% stable disease or better; two complete responses lasting 7.5 and 66+ months.","Preclinical data support combining MB-101 with oncolytic virus MB-108 to improve efficacy.","Company notes development of MB-109 program is contingent on raising additional funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176197,"accession_number":"0001104659-25-020900","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Mustang Bio regains compliance with Nasdaq minimum stockholders' equity requirement; listing matters closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Feb 26, 2025 notice from Nasdaq confirming compliance with minimum stockholders' equity rule (Rule 5550(b)(1)).","Previously regained compliance with minimum bid price rule; now meets all Nasdaq Capital Market listing criteria.","Subject to Panel Monitor for one year through Feb 26, 2026; non-compliance triggers hearing without plan submission.","Press release issued March 5, 2025 announcing the compliance determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176196,"accession_number":"0001104659-25-018299","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Mustang Bio sells fixed assets to AbbVie for $1M, exits Worcester facility","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of furniture, fixtures, equipment to AbbVie for $1.0M; lease terminated.","Exits manufacturing facility in Worcester, MA; corporate HQ moved to Waltham, MA.","Expects ~$2.0M cash savings over 24 months from lease termination.","Plans to rely on academic partners and contract manufacturers for clinical trials.","Aims to initiate MB-109 (HSV-1 oncolytic virus + CAR-T) trial for GBM in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176195,"accession_number":"0001104659-25-016145","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mustang Bio shareholders approve issuance of up to 5.48M shares underlying warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Written consent signed by holders of ~56% of voting power authorizing warrant share issuance under Nasdaq Rule 5635(d).","Issuance covers up to 5,475,082 shares of common stock underlying warrants issued to H.C. Wainwright & Co. and accredited investors.","Consent holders: 131,052 common shares and 250,000 Class A Preferred shares (each with ~8.4 votes).","Definitive information statement on Schedule 14C to be filed and sent to stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176194,"accession_number":"0001104659-25-013029","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Mustang Bio sells FF&E for $1M, terminates Worcester lease; expects ~$2M savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold FF&E to AbbVie for $1.0M cash; lease termination expected to save ~$2.0M in lease obligations.","Lease base term (ending Oct 2026) terminated early; company to vacate 377 Plantation St within ~20 business days.","Waived lease extension options; no further rent or operating expenses after Early Termination Date.","Escrow agent holds purchase price pending inspection of FF&E condition; agreement provides for price adjustment if FF&E insufficient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176193,"accession_number":"0001104659-25-011517","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Mustang Bio closes $8M public offering, regains Nasdaq minimum bid compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced $8M offering of 2.66M shares (or equivalents) and Series C-1/C-2 warrants at $3.01 per unit; closed Feb 10, 2025.","Net proceeds ~$6.9M; warrants exercisable upon stockholder approval at $3.01/share.","Received Nasdaq notice of compliance with Bid Price Rule (minimum bid $1.00) after 1-for-50 reverse stock split on Jan 15.","Company believes it now meets Nasdaq equity rule ($2.5M minimum) following offering; awaiting formal determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176192,"accession_number":"0001104659-25-004565","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Mustang Bio effects 1-for-50 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Outstanding shares reduced from ~64.8M to ~1.3M; split effective Jan 15, 2025.","Trading on split-adjusted basis under symbol MBIO begins Jan 16, 2025.","Reverse split intended to meet Nasdaq's $1.00 minimum bid price requirement.","No fractional shares issued; cash payment in lieu for fractional entitlements.","New CUSIP 62818Q302; board set final ratio on Jan 6, 2025 per prior stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176191,"accession_number":"0001104659-25-002599","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mustang Bio stockholders authorize issuance of up to 34.8M shares underlying warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders representing ~57% voting power executed written consent approving warrant share issuance.","Up to 34,767,934 shares of common stock may be issued under warrants to an institutional investor and H.C. Wainwright.","Issuance complies with Nasdaq Listing Rule 5635(d) for transactions exceeding 20% of outstanding shares.","Consent includes 6,552,781 common shares and 250,000 Class A Preferred shares (each with 285 votes).","Previously disclosed Inducement Letter (Oct 24, 2024) and Engagement Letter (Oct 23, 2024) are the basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176190,"accession_number":"0001104659-25-000343","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mustang Bio shareholders elect seven directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with at least 58.3M votes for each; broker non-votes none.","KPMG LLP ratified as independent auditor for FY 2024 with 59.4M for, 62.7K against, 30.6K abstain.","Approximately 58% of total votes were represented at the virtual annual meeting on Dec. 26, 2024.","Outstanding shares: 48.8M common, 0.8M Class A common, 0.25M Class A preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193090,"accession_number":"0001104659-24-119756","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Mustang Bio receives Nasdaq delist notice but granted extension; interim CFO resigns, CEO takes over","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Staff issued delist determination on Nov 13, 2024 for non-compliance with bid price rule.","Nasdaq Hearings Panel granted extension to Jan 31, 2025 for bid price and Feb 18, 2025 for equity rule compliance.","James Murphy resigned as Interim CFO on Nov 12, 2024; no disagreement involved.","President/CEO Manuel Litchman appointed Interim CFO effective Nov 15, 2024; previously held role in Dec 2023-Jan 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193089,"accession_number":"0001104659-24-114835","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Mustang Bio schedules Dec 26, 2024 annual meeting; sets proposal deadlines Nov 16/18","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting set for December 26, 2024; time/location to be in proxy statement.","Rule 14a-8 proposals for proxy inclusion must be received by November 18, 2024.","Director nominations and non-14a-8 proposals must be submitted by November 16, 2024.","Universal proxy rule compliance also requires notice by November 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193088,"accession_number":"0001104659-24-111500","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Mustang Bio raises $4M via warrant exercise; appoints David Jin to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor exercised 16,877,638 existing warrants at $0.237/share for ~$4M gross proceeds, before fees.","Issued new unregistered warrants to purchase up to 33,755,276 shares at $0.27/share; exercisable after stockholder approval.","Board expanded to seven; David Jin (CFO of majority owner Fortress Biotech) appointed as director.","Net proceeds to be used for working capital and general corporate purposes.","H.C. Wainwright acted as placement agent with 7% cash fee and 1,012,658 placement agent warrants at $0.2963/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209466,"accession_number":"0001104659-24-099829","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Mustang Bio receives Nasdaq delisting notice for failure to meet equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff determined to delist MBIO due to non-compliance with $2.5M stockholders' equity requirement by Sept 9, 2024 extension deadline.","Company intends to request a hearing before Nasdaq Hearings Panel, which will stay delisting pending hearing and any granted extension.","Trading on Nasdaq Capital Market under symbol MBIO continues pending the hearing process.","No assurance that Panel will grant continued listing or that compliance can be shown within any extension period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209465,"accession_number":"0001104659-24-077596","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","1.02","2.01","5.07","9.01"],"status":"ready","headline":"Mustang Bio repurchases previously sold assets for $1.4M; shareholders approve reverse split and warrant share issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company to repurchase assets from uBriGene for $1,395,138; $100K upfront, $1,295,138 deferred for 12 months with possible extensions.","Shareholders approved issuance of up to 60,731,608 shares underlying warrants, representing over 20% of outstanding common stock.","Shareholders also authorized a reverse stock split between 1-for-10 and 1-for-50, with Board to determine exact ratio.","Repurchase is an Expedited Divestment under CFIUS National Security Agreement signed May 13, 2024, reversing the prior sale.","Company may defer deferred payment if net assets fall below $20M; unpaid amounts accrue 5% interest after 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227520,"accession_number":"0001104659-24-074043","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Mustang Bio raises $2.5M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3,025,000 common shares and 3,105,000 pre-funded warrants (collectively 6,130,000 shares/equivalents) at $0.41/unit.","Concurrent private placement of 6,130,000 warrants with $0.41 exercise price, exercisable after stockholder approval for 5 years.","Gross proceeds ~$2.5M; net proceeds for working capital and general corporate purposes.","H.C. Wainwright as placement agent; paid 7% cash fee plus warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227519,"accession_number":"0001104659-24-069131","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Mustang Bio enters $5.6M ATM offering with H.C. Wainwright; terminates prior $100M agreement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["May 31, 2024: ATM Offering Agreement with H.C. Wainwright for up to $5.6M of common stock; 3.0% commission to manager.","Prior $100M ATM Sales Agreement with B. Riley Securities & others terminated effective June 5, 2024.","New S-3 registration statement (File No. 333-279891) filed same day enables the at-the-market offering.","Company not obligated to sell any shares; offering ends upon full sale or termination of agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227518,"accession_number":"0001558370-24-008535","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Mustang Bio receives second Nasdaq deficiency notice; stock bid below $1 for 31 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Mustang Bio on May 16, 2024 that bid price closed below $1 for 31 consecutive business days.","Company has 180 days, until November 12, 2024, to regain compliance by closing at $1.00 or more for 10+ days.","Prior stockholders' equity deficiency: Nasdaq granted extension through September 9, 2024 to regain compliance.","If not cured, Mustang may seek a second grace period or request a hearing to avoid delisting.","No decision yet on reverse stock split or other remedy; delisting risk remains if compliance is not achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227517,"accession_number":"0001104659-24-056459","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Mustang Bio closes $4M public offering of shares and warrants; amends existing warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4M from offering of shares and warrants at $0.237 per combined unit.","Net proceeds ~$3.3M; potential additional $12M if all series A-1, A-2, A-3 warrants cash-exercised.","Amended 2,588,236 existing warrants from $1.58 to $0.237 exercise price effective May 2.","Offering includes 16.9M shares and three series of warrants each for 16.9M shares.","H.C. Wainwright acted as placement agent; proceeds for working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227516,"accession_number":"0001104659-24-053706","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Mustang Bio prelim Q1 cash $1.3M, operating burn $5.3M, cash runway concerns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and equivalents as of March 31, 2024: approximately $1.3 million.","Cash used in operating activities for Q1 2024: approximately $5.3 million.","Results are preliminary and subject to completion of closing procedures; actual results may differ.","Company cautions not to place undue reliance on these estimates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227515,"accession_number":"0001558370-24-005022","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Mustang Bio cuts workforce by 81% amid CFIUS uncertainty and facility sale to uBriGene","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved ~81% workforce reduction to reduce costs and preserve capital due to fundraising environment and CFIUS review of facility sale.","Workforce reduction expected substantially complete in Q2 2024; expects ~$0.2M in one-time termination cash expenditures.","Company continues to evaluate all strategic and other alternatives related to the business.","Sale of leasehold interest and assets to uBriGene (Chinese CDMO) pending CFIUS review; terms not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246358,"accession_number":"0001104659-24-041199","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mustang Bio provides CFIUS update on facility sale to uBriGene; investigation due by May 13, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Transaction involves sale of Worcester cell processing facility and manufacturing assets to uBriGene.","CFIUS review entered a second 45-day investigation period ending May 13, 2024.","CFIUS clearance not a condition to closing but may affect timing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246357,"accession_number":"0001104659-24-035016","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Mustang Bio receives Nasdaq delisting notice for equity shortfall; 45 days to submit compliance plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $123,000 falls short of Nasdaq's $2.5M minimum for continued listing.","Company has until April 29, 2024 to submit a plan to regain compliance.","If plan is accepted, Nasdaq may grant a 180-day extension; otherwise Company can appeal.","Trading continues on Nasdaq under MBIO with no immediate effect on listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246356,"accession_number":"0001104659-24-033015","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mustang Bio reports FY2023 net loss of $51.6M; cash drops to $7.0M; MB-106 data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $7.0M at Dec 31, 2023, down from $76.7M at Dec 31, 2022; $30.4M debt termination payment in 2023.","Net loss $51.6M ($6.00/share) vs $77.5M ($10.09/share) in 2022; R&D spend $40.5M vs $62.5M.","MB-106 Phase 1/2 multicenter trial: 100% ORR in FL (n=5 all CR) and WM (n=3 with VGPR/PR); no severe CRS/ICANS.","Registrational trial in Waldenstrom macroglobulinemia planned H2 2024; topline expected H2 2026; RMAT designation request H1 2024.","Closed uBriGene asset sale for $6M upfront; $5M contingent; lease assignment subject to CFIUS review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246355,"accession_number":"0001104659-24-023665","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mustang Bio and uBriGene withdraw and re-file CFIUS notice; new 45-day review period begins Feb 13","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Feb 12, 2024, CFIUS granted request to withdraw and re-file the joint voluntary notice for the transaction.","New 45-day review period started Feb 13, 2024, concluding no later than March 28, 2024.","If CFIUS does not conclude by March 28, the proceeding will transition to a second 45-day investigation phase.","The CFIUS review relates to Mustang's sale of its Worcester cell processing facility and associated assets to uBriGene.","CFIUS clearance was not a condition to closing the transaction, but is being pursued voluntarily."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246354,"accession_number":"0001104659-24-006668","cik":1680048,"company_name":"MUSTANG BIO, INC.","ticker":"MBIO","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mustang Bio appoints James Murphy as Interim CFO effective Jan 19, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Murphy appointed Interim CFO, serving as Principal Financial and Accounting Officer.","Murphy provides consulting services via Danforth Advisors; receives no direct compensation from Mustang.","Murphy has served as interim CFO for public and private life science companies since 2012.","No family relationships or material transactions exist between Murphy and Mustang's officers or directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4783678.473254901,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}